Dry Eye Syndrome Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

DUBLIN--()--The "Dry Eye Syndrome Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Disease Overview

Dry eye syndrome, also known as dry eye disease, keratitis sicca and keratoconjunctivitis sicca, is a form of ocular surface and tears disease that results in problems in vision, discomfort and tear film instability, causing potential damage to the ocular surface.

It can also overlap with other causes of ocular surface disease such as meibomian gland dysfunction and ocular allergy.

The ocular surface consists of seven components including the lacrimal and accessory lacrimal apparatus, the tear film, the nasolacrimal drainage system, the bulbar and tarsal conjunctiva, the eyelids, cranial nerve V and cranial nerve VII.

Any abnormalities or deficiencies in one of these ocular surface components may worsen the condition of dry eye syndrome in a patient.

Dry eye syndrome is categorized into two types which includes dry eye syndrome associated with sjögren syndrome and dry eye syndrome unassociated with sjögren syndrome. Dry eye syndrome can also be sub-divided into pure aqueous deficiency dry eye and evaporative dry eye.

Some of the symptoms associated with dry eye syndrome include hyperemia, ocular irritation, mucoid discharge, excessive tearing, blurred vision, photophobia, ocular dryness and grittiness.

Dry eye syndrome can be treated by using lubricating supplements that includes artificial tear substitutes, gels, emulsions, ointments, topical anti-inflammatory agents such as topical cyclosporine, topical corticosteroids, topical or systemic tetracyclines, topical hyaluronic acid, autologous or umbilical cord serum, systemic immunosuppressants and topical or systemic omega-3 fatty acids.

Key players (developing drugs for the treatment of dry eye syndrome)

  • Ocular Therapeutix, Inc.,
  • LTT Bio-Pharma,
  • HanAll BioPharma Co., Ltd.
  • and others.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Dry Eye Syndrome Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/sw8qq8/dry_eye_syndrome

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Optical Disorders Drugs